相关实验视频
Updated: Jun 16, 2025

A Human Ex Vivo Atherosclerotic Plaque Model to Study Lesion Biology
Published on: May 6, 2014
激活X因子抑制改善NF-κB-IL-6 - - 介导周血管炎症和肺高血压
Satomi Imakiire1,2, Keiji Kimuro1,2, Keimei Yoshida1,2
1Department of Cardiovascular Medicine, Faculty of Medical Sciences, Kyushu University, Fukuoka, Japan.
激活X因子 (FXa) 抑制通过减少炎症和血管重塑来改善肺动脉高血压 (PAH). 这项研究表明FXa是PAH治疗的潜在治疗标.
科学领域:
- 心血管研究研究心血管研究
- 肺高血压是什么意思 肺高血压
- 炎症和免疫学 炎症和免疫学
背景情况:
- 激活X因子 (FXa) 通过蛋白酶激活受体 (PAR1/PAR2) 促进炎症和细胞增殖.
- 肺动脉高血压 (PAH) 涉及炎症反应和血管重塑.
研究的目的:
- 调查FXa在肺动脉高血压 (PAH) 的发展中的作用.
- 探索FXa对PAH影响的潜在机制.
主要方法:
- 评估了埃多克萨班 (FXa 抑制剂) 在单胺诱导的PAH大鼠模型中的作用.
- 评估了血液动力学参数,右心室缩和血管改造.
- 在老鼠肺部和患者衍生的肺动脉光滑肌细胞 (PASMCs) 中分析了FXa,PAR1,PAR2和IL-6水平.
主要成果:
- 埃多克萨班治疗改善了PAH大鼠右心室缩压升高 (RVSP),肺血管阻力和血管重塑.
- 抑制FXa降低了老鼠肺中的NF-κB活性和IL-6mRNA水平.
- 通过PAR1激活,FXa刺激增加了PASMC的增殖和IL-6的产生.
结论:
- 在PAH中,FXa抑制减轻NF-κB-IL-6介导的炎症和血管重塑.
- 在PAH的发展中,FXa起着重要的作用.
- 抑制FXa是一种潜在的治疗策略,用于治疗PAH.
更多相关视频
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
相关概念视频
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Regulation of Angiogenesis and Blood Supply
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
The JAK-STAT Signaling Pathway
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...